Lerdelimumab
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameLerdelimumab
Drug Alias Name +[7]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesCambridge Antibody TechnologyGenzyme Corp
Active IndicationsN/A
Inactive Indications